Does Switching from Tamoxifen to an Aromatase Inhibitor Result in Weight Change in Postmenopausal Breast Cancer Patients?~!2010-04-23~!2010-07-08~!2010-07-26~!
Abstract
Background: Women treated with early stage breast cancer often gain weight following diagnosis.Tamoxifen and aromatase inhibitor (AI)-treated patients experience similar weight gains in randomized clinical trials after five years of adjuvant therapy.How switching therapies affects weight change is uncertain.Purpose: To determine the degree of weight change at the time of switching from tamoxifen to an aromatase inhibitor during adjuvant hormonal therapy, and to identify possible associations.Methods: Retrospective review of postmenopausal women with non-metastatic, invasive, hormone receptor-positive breast cancer sequenced from tamoxifen to an AI.Weights and height were recorded while on tamoxifen, 12 and 6 months prior to switching, at the time of the switch and 6 and 12 months post-switch.Variables included age at diagnosis, adjuvant chemotherapy, body-mass index (BMI), antidepressant use, co-morbidities, and menopausal status.Results: Data on 80 eligible patients revealed mean weight change from 12 months prior to 12 months post-switch was 0.7 kg (95%CI: -0.16, 1.5 kg, p=.11) with most of the change occurring before the switch.No significant difference was found between weights obtained from the time of switch to 12 months after (mean change -0.1 kg; 95% CI: -0.74, 0.53, p=.75).No association with age, stage, BMI, menopausal status, specific AI, duration of tamoxifen, adjuvant chemotherapy, alcohol or antidepressant use was found.Conclusions: While patients switching…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 80 participants or records.
Read the paper
Related studies
- A Coupled SYSTEM of Intracellular Ca 2+ Clocks and Surface Membrane Voltage Clocks Controls the Timekeeping Mechanism of the Heart’s Pacemaker
- A Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. in Relation to its Major Active Constituent Curcumin
- Cancer epigenetics: Moving forward
- Current developments in LC-MS for pharmaceutical analysis
- Myricetin: A comprehensive review on its biological potentials
- A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.